FindMyMoney.App
Opportunity

Exploratory/Developmental Grant (R21) | NIH

NIH R21 guidance for exploratory high-risk projects, including current due-date cycles and budget structure.

JJ Ben-Joseph
JJ Ben-Joseph
💰 Funding Up to $275,000 total direct costs over two years, with no more than $200,000 direct costs in any single year (unless FOA states otherwise)
📅 Deadline Recurring standard NIH due dates for new applications: February 16, June 16, October 16
📍 Location United States, Global (institution and FOA dependent)
🏛️ Source National Institutes of Health
Apply Now

Status Update (February 2026)

For opportunities using NIH standard due dates, new R21 applications are generally due February 16, June 16, and October 16.

NIH also indicates a transition for AIDS due dates: for applications due on or after May 25, 2026, dedicated AIDS due dates are being retired. Confirm dates on your selected NOFO before submission.

What the R21 Is For

R21 supports exploratory/developmental work where technical uncertainty is high but potential payoff is strong. It is designed for focused, early-stage projects that can produce decisive feasibility signals, not full-scale mature programs.

Budget and Duration Constraints

Under standard R21 policy language:

  • up to 2 years total,
  • up to $275,000 direct costs total,
  • no more than $200,000 direct costs in any one year.

Some FOAs can modify these defaults, so always prioritize the NOFO’s own budget section.

Current Parent R21 Tracks

NIH parent announcements currently include:

  • PA-25-304 (Clinical Trial Not Allowed)
  • PA-25-306 (Clinical Trial Required)
  • PA-25-307 (Basic Experimental Studies with Humans Required)

Use the correct one for your project design. Choosing the wrong track is a common avoidable error.

Current parent notices list an expiration date in early 2028, with recurring due-date cycles in 2026 and 2027. That gives applicants a defined planning runway, but institute priorities and participation can still shift, so always re-check the active NOFO before drafting.

How to Apply

  1. Select the correct active R21 NOFO for your clinical-trial status.
  2. Confirm institute/center participation and mission fit.
  3. Build a 2-year plan with explicit go/no-go milestones.
  4. Align budget with a limited exploratory scope.
  5. Submit through Grants.gov/eRA Commons and resolve validation issues quickly.

Common Mistakes

  • Submitting an R01-scale scope in an R21 framework.
  • Weak milestone discipline for high-risk aims.
  • Budgets that are mismatched to stated deliverables.
  • Ignoring parent-announcement differences by trial category.
  • Using stale due-date assumptions.

Review-Focused Tip

Write aims and milestones so a reviewer can clearly see what “success by year 2” means and what evidence will justify a follow-on mechanism (often R01 or equivalent). This improves both significance and feasibility scoring.

When R21 Is Not the Right Fit

If your project depends on large cohorts, long follow-up periods, or broad infrastructure buildout before any interpretable result, R21 is often the wrong mechanism. In those cases, discuss alternatives with NIH program staff early instead of forcing an oversized project into a 2-year exploratory format. A mechanism-fit check before drafting can save months of misaligned writing and improve your eventual funding odds.

Due-Date Policy Change Reminder

NIH policy notice NOT-OD-26-029 updates AIDS due-date handling for applications due on or after May 25, 2026. If your project previously relied on dedicated AIDS receipt dates, confirm the current due-date path in NIH’s standard due-date guidance and your selected NOFO before final submission planning.

Official Sources